NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
Publication
, Journal Article
Zelenetz, AD; Gordon, LI; Chang, JE; Christian, B; Abramson, JS; Advani, RH; Bartlett, NL; Budde, LE; Caimi, PF; De Vos, S; Dholaria, B; Hu, B ...
Published in: J Natl Compr Canc Netw
November 2021
In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody-drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1-mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
November 2021
Volume
19
Issue
11
Start / End Page
1218 / 1230
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Lymphoma, Non-Hodgkin
- Lymphoma, Large B-Cell, Diffuse
- Immunotherapy, Adoptive
- Immunoconjugates
- Humans
- Antigens, CD19
- Adult
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Zelenetz, A. D., Gordon, L. I., Chang, J. E., Christian, B., Abramson, J. S., Advani, R. H., … Sundar, H. (2021). NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. J Natl Compr Canc Netw, 19(11), 1218–1230. https://doi.org/10.6004/jnccn.2021.0054
Zelenetz, Andrew D., Leo I. Gordon, Julie E. Chang, Beth Christian, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, et al. “NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.” J Natl Compr Canc Netw 19, no. 11 (November 2021): 1218–30. https://doi.org/10.6004/jnccn.2021.0054.
Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, et al. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. J Natl Compr Canc Netw. 2021 Nov;19(11):1218–30.
Zelenetz, Andrew D., et al. “NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.” J Natl Compr Canc Netw, vol. 19, no. 11, Nov. 2021, pp. 1218–30. Pubmed, doi:10.6004/jnccn.2021.0054.
Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. J Natl Compr Canc Netw. 2021 Nov;19(11):1218–1230.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
November 2021
Volume
19
Issue
11
Start / End Page
1218 / 1230
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Lymphoma, Non-Hodgkin
- Lymphoma, Large B-Cell, Diffuse
- Immunotherapy, Adoptive
- Immunoconjugates
- Humans
- Antigens, CD19
- Adult
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis